Shifting Seamlessly
From EUA to 510(k)
for COVID-19 Assays

COVID-19 diagnostics marketed under Emergency Use Authorization (EUA) are transitioning to comply with US FDA 510(k)/de novo requirements to remain on the market in the United States. Precision for Medicine experts are here to guide you through the process for clearance.

Regulatory, Clinical, and Quality Steps Required to Move From EUA to 510(k) Clearance

Since the emergence of the COVID-19 pandemic, an intense research effort has been focused on swiftly bringing diagnostic tests to market under EUA. Now, with the availability of 3 COVID-19 vaccines, we are seeing a steady increase in population immunity. Although the COVID-19 Public Health Emergency remains in effect, the FDA has already issued draft guidances on transition plans for devices under an EUA. Therefore, we expect manufacturers of diagnostics with EUAs to start transitioning to marketing submission, as the FDA has granted the first de novo and cleared the first molecular 510(k). A de novo has not been granted for an antigen or over-the-counter test.
With hundreds of COVID-19 assays with EUA potentially transitioning to 510(k) clearance in a short period, plans should now be made for the necessary analytical and clinical validation studies and regulatory submissions.
Precision for Medicine supports the efforts of companies developing COVID-19 diagnostics with:
  • COVID-19 biospecimens sourced from our clinics and biobank
  • Deep practical experience with COVID-19 EUAs, and 510(k) clearances for diagnostic tests
  • Broad expertise in evolving US and EU diagnostic regulations
  • Comprehensive lab support for immune monitoring, antibody characterization, and related research

Precision’s Unmatched Experience in Diagnostic Development Takes Your COVID-19 Product From Bench to Bedside

Speak With an Expert About Your EUA Transition

With hundreds of Emergency Use– authorized COVID-19 assays potentially transitioning to 510(k) clearance in a short period, you should plan now for the necessary validation studies and regulatory filings.

Regulatory Strategy & Submissions Experience


IVD pre-submissions, preclinical/ clinical trial designs and executions


Marketing clearances and approvals for IVD submissions


Companion diagnostics regulatory filings in countries around the globe

Market Access and Commercialization Strategy & Support Experience

100+ successful diagnostics market access, strategy, and tactical project completions
Global experience in 15+ markets on 3 continents